Literature DB >> 17079299

Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.

Evelien M Bunnik1, Esther D Quakkelaar, Ad C van Nuenen, Brigitte Boeser-Nunnink, Hanneke Schuitemaker.   

Abstract

CXCR4-using (X4) human immunodeficiency virus type 1 (HIV-1) variants evolve from CCR5-using (R5) variants relatively late in the natural course of infection in 50% of HIV-1 subtype B-infected individuals and subsequently coexist with R5 HIV-1 variants. This relatively late appearance of X4 HIV-1 variants is poorly understood. Here we tested the neutralization sensitivity for soluble CD4 (sCD4) and the broadly neutralizing antibodies IgG1b12, 2F5, 4E10, and 2G12 of multiple coexisting clonal R5 and (R5)X4 (combined term for monotropic X4 and dualtropic R5X4 viruses) HIV-1 variants that were obtained at two time points after the first appearance of X4 variants in five participants of the Amsterdam Cohort Studies on HIV-1 infection and AIDS. Recently emerged (R5)X4 viruses were significantly more sensitive to neutralization by the CD4-binding-site-directed agents sCD4 and IgG1b12 than their coexisting R5 viruses. This difference was less pronounced at the later time point. Early (R5)X4 variants from two out of four patients were also highly sensitive to neutralization by autologous serum (50% inhibition at serum dilutions of >200). Late (R5)X4 viruses from these two patients were neutralized at lower serum dilutions, which suggested escape of X4 variants from humoral immunity. Autologous neutralization of coexisting R5 and (R5)X4 variants was not observed in the other patients. In conclusion, the increased neutralization sensitivity of HIV-1 variants during the transition from CCR5 usage to CXCR4 usage may imply an inhibitory role for humoral immunity in HIV-1 phenotype evolution in some patients, thus potentially contributing to the late emergence of X4 variants.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17079299      PMCID: PMC1797458          DOI: 10.1128/JVI.01983-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1.

Authors:  Bing Li; Julie M Decker; Roy W Johnson; Frederic Bibollet-Ruche; Xiping Wei; Joseph Mulenga; Susan Allen; Eric Hunter; Beatrice H Hahn; George M Shaw; Jerry L Blackwell; Cynthia A Derdeyn
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

2.  Identification of a major co-receptor for primary isolates of HIV-1.

Authors:  H Deng; R Liu; W Ellmeier; S Choe; D Unutmaz; M Burkhart; P Di Marzio; S Marmon; R E Sutton; C M Hill; C B Davis; S C Peiper; T J Schall; D R Littman; N R Landau
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

3.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Authors:  T Dragic; V Litwin; G P Allaway; S R Martin; Y Huang; K A Nagashima; C Cayanan; P J Maddon; R A Koup; J P Moore; W A Paxton
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

4.  HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.

Authors:  Y Feng; C C Broder; P E Kennedy; E A Berger
Journal:  Science       Date:  1996-05-10       Impact factor: 47.728

5.  Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants.

Authors:  L H Ping; J A Nelson; I F Hoffman; J Schock; S L Lamers; M Goodman; P Vernazza; P Kazembe; M Maida; D Zimba; M M Goodenow; J J Eron; S A Fiscus; M S Cohen; R Swanstrom
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

6.  Amino acid substitutions in the V3 loop are responsible for adaptation to growth in transformed T-cell lines of a primary human immunodeficiency virus type 1.

Authors:  G Harrowe; C Cheng-Mayer
Journal:  Virology       Date:  1995-07-10       Impact factor: 3.616

7.  Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus.

Authors:  J Veenstra; R Schuurman; M Cornelissen; A B van't Wout; C A Boucher; H Schuitemaker; J Goudsmit; R A Coutinho
Journal:  Clin Infect Dis       Date:  1995-09       Impact factor: 9.079

8.  Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection.

Authors:  M Koot; A B van 't Wout; N A Kootstra; R E de Goede; M Tersmette; H Schuitemaker
Journal:  J Infect Dis       Date:  1996-02       Impact factor: 5.226

9.  Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment.

Authors:  M Groenink; J P Moore; S Broersen; H Schuitemaker
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.

Authors:  Q J Sattentau; J P Moore
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

View more
  29 in total

1.  A haplotype in the CCR5 gene promoter was associated with the susceptibility to HIV-1 infection in a northern Chinese population.

Authors:  Lidan Xu; Yuandong Qiao; Xuelong Zhang; Haiming Sun; Jingwei Wang; Donglin Sun; Xueyuan Jia; Chao Shen; Yanling Zhao; Yan Jin; Yang Yu; Hong Ling; Kaili Wang; Songbin Fu
Journal:  Mol Biol Rep       Date:  2010-04-04       Impact factor: 2.316

2.  A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays.

Authors:  Michael D Alpert; Lisa N Heyer; David E J Williams; Jackson D Harvey; Thomas Greenough; Maria Allhorn; David T Evans
Journal:  J Virol       Date:  2012-08-29       Impact factor: 5.103

3.  SDF-1/CXCL12 production by mature dendritic cells inhibits the propagation of X4-tropic HIV-1 isolates at the dendritic cell-T-cell infectious synapse.

Authors:  Nuria González; Mercedes Bermejo; Esther Calonge; Clare Jolly; Fernando Arenzana-Seisdedos; José L Pablos; Quentin J Sattentau; José Alcamí
Journal:  J Virol       Date:  2010-02-24       Impact factor: 5.103

4.  Existence of Replication-Competent Minor Variants with Different Coreceptor Usage in Plasma from HIV-1-Infected Individuals.

Authors:  Yosuke Maeda; Taichiro Takemura; Takayuki Chikata; Takeo Kuwata; Hiromi Terasawa; Riito Fujimoto; Nozomi Kuse; Tomohiro Akahoshi; Hayato Murakoshi; Giang Van Tran; Yu Zhang; Chau Ha Pham; Anh Hong Quynh Pham; Kazuaki Monde; Tomohiro Sawa; Shuzo Matsushita; Trung Vu Nguyen; Kinh Van Nguyen; Futoshi Hasebe; Tetsu Yamashiro; Masafumi Takiguchi
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

5.  Evolution of HIV-1 coreceptor usage and coreceptor switching during pregnancy.

Authors:  Doris G Ransy; Alena Motorina; Natacha Merindol; Bertine S Akouamba; Johanne Samson; Yolanda Lie; Laura A Napolitano; Normand Lapointe; Marc Boucher; Hugo Soudeyns
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-25       Impact factor: 2.205

6.  Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4.

Authors:  Gregory Q Del Prete; Beth Haggarty; George J Leslie; Andrea P O Jordan; Josephine Romano; Nathaniel Wang; Jianbin Wang; Michael C Holmes; David C Montefiori; James A Hoxie
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

Review 7.  Chemokine receptors and co-stimulatory molecules: unravelling feline immunodeficiency virus infection.

Authors:  Brian J Willett; Margaret J Hosie
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

8.  Dendritic cells preferentially transfer CXCR4-using human immunodeficiency virus type 1 variants to CD4+ T lymphocytes in trans.

Authors:  Thijs van Montfort; Adri A M Thomas; Georgios Pollakis; William A Paxton
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

9.  R5X4 viruses are evolutionary, functional, and antigenic intermediates in the pathway of a simian-human immunodeficiency virus coreceptor switch.

Authors:  Silvana Tasca; Siu-Hong Ho; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

10.  Understanding the HIV coreceptor switch from a dynamical perspective.

Authors:  Christel Kamp
Journal:  BMC Evol Biol       Date:  2009-11-30       Impact factor: 3.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.